Post-transplant cyclophosphamide pharmacokinetics and haploidentical hematopoietic cell transplantation outcomes: an exploratory study

References

• Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(2):132.
   PubMedGoogle Scholar
• Wachsmuth LP, Patterson MT, Eckhaus MA, et al. Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression. J Clin Invest. 2019;129(6):2357–2373.
   PubMed Web of Science ®Google Scholar
• Im A, Rashidi A, Wang T, et al. Risk factors for graft-versus-Host disease in haploidentical hematopoietic cell transplantation using post-transplant cyclophosphamide. Biol Blood Marrow Transplant. 2020;26(8):1459–1468.
   PubMed Web of Science ®Google Scholar
• McDonald GB, McCune JS, Batchelder A, et al. Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. Clin Pharmacol Ther. 2005;78(3):298–308.
   PubMed Web of Science ®Google Scholar
• Ren S, Kalhorn TF, McDonald GB, et al. Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients. Clin Pharmacol Ther. 1998;64(3):289–301.
   PubMed Web of Science ®Google Scholar
• McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003;101(5):2043–2048.
   PubMed Web of Science ®Google Scholar
• McCune JS, Batchelder A, Guthrie KA, et al. Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy. Clin Pharmacol Ther. 2009;85(6):615–622.
   PubMed Web of Science ®Google Scholar
• Salinger DH, McCune JS, Ren AG, et al. Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach. Clin Cancer Res. 2006;12(16):4888–4898.
   PubMed Web of Science ®Google Scholar
• Hassan M, Andersson BS. Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. Pharmacogenomics. 2013;14(1):75–87.
   PubMed Web of Science ®Google Scholar
• Rocha V, Porcher R, Fernandes JF, et al. Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia. Leukemia. 2009;23(3):545–556.
   PubMed Web of Science ®Google Scholar
• Ekhart C, Rodenhuis S, Smits PH, et al. Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin. Pharmacogenet Genomics. 2008;18(11):1009–1015.
   PubMed Web of Science ®Google Scholar
• Rambaldi B, Kim HT, Reynolds C, et al. Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Adv. 2021;5(2):352–364.
   PubMed Web of Science ®Google Scholar
• McCurdy SR, Radojcic V, Tsai HL, et al. Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning. Blood. 2022;139(4):608–623.
   PubMed Web of Science ®Google Scholar
• Kanakry CG, Ganguly S, Zahurak M, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013;5(211):211ra157.
   PubMed Web of Science ®Google Scholar
• Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the mount Sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22(1):4–10.
   PubMed Web of Science ®Google Scholar
• Jagasia MH, Greinix HT, Arora M, et al. National institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389–401.e1.
   PubMed Web of Science ®Google Scholar
• Ruggeri A, Labopin M, Ciceri F, et al. Definition of GvHD-free, relapse-free survival for registry-based studies: an ALWP-EBMT analysis on patients with AML in remission. Bone Marrow Transplant. 2016;51(4):610–611.
   PubMed Web of Science ®Google Scholar
• Ekhart C, Gebretensae A, Rosing H, et al. Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2007;854(1-2):345–349.
   PubMed Web of Science ®Google Scholar
• Kalhorn TF, Howald WN, Cole S, et al. Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2006;835(1–2):105–113.
   PubMed Web of Science ®Google Scholar
• Shanker Kasudhan K, Patial A, Mehra N, et al. Cyclophosphamide, hydroxycyclophosphamide and carboxyethyl phosphoramide mustard quantification with liquid chromatography mass spectrometry in a single run human plasma samples: a rapid and sensitive method development. J Chromatogr B Analyt Technol Biomed Life Sci. 2022;1198:123228.
   PubMed Web of Science ®Google Scholar
• Ekhart C, Doodeman VD, Rodenhuis S, et al. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics. 2008;18(6):515–523.
   PubMed Web of Science ®Google Scholar
• Bemer MJ, Sorror M, Sandmaier BM, et al. A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients. Cancer Chemother Pharmacol. 2013;72(3):607–618.
   PubMed Web of Science ®Google Scholar
• Karaesmen E, Rizvi AA, Preus LM, et al. Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. Blood. 2017;130(13):1585–1596.
   PubMed Web of Science ®Google Scholar
• Leather HL. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant. 2004;33(2):137–152.
   PubMed Web of Science ®Google Scholar
• McCune JS, Bemer MJ. Pharmacokinetics, pharmacodynamics and pharmacogenomics of immunosuppressants in allogeneic haematopoietic cell transplantation: part I. Clin Pharmacokinet. 2016;55(5):525–550.
   PubMed Web of Science ®Google Scholar
• McAdams MJ, Hyder M, Dimitrova D, et al. Phase I/II study of reduced dosing of post-transplantation cyclophosphamide (PTCy) after HLA-haploidentical bone marrow transplantation. Blood. 2021;138(Supplement 1):101–101.
   Google Scholar
• Wachsmuth LP, Patterson MT, Eckhaus MA, et al. Optimized timing of post-transplantation cyclophosphamide in MHC-Haploidentical murine hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26(2):230–241.
   PubMed Web of Science ®Google Scholar